tbuckley/cabot-search huggingface dataset:
Phenindione Sensitivity
Authors: A. Hollman, H. O. Wong
Journal: BMJ (1964)

One hundred and seven patients, 46 males and 61 females, who were attending for treatment of hypertension were assessed from the standpoint of the presence or absence of evidence of coronary artery disease.An oral glucose-tolerance test was carried out on each patient.It was found that of all patients in the study group with evidence of coronary artery disease there were 35% with abnormal glucose tolerance whereas in those patients with no symptoms of coronary disease there were only 16%' with abnormal tests.A higher percentage of patients with abnormal glucose tolerance was also noted in those in whom the only evidence of ischaemic heart disease was STsegment depression in the electrocardiogram after exercise.The basal blood-pressure was not significantly different between those patients with and those without evidence of ischaemic heart disease.The helpful criticism and encouragement of Sir Horace Smirk in the preparation of this paper are gratefully acknowledged.My thanks are also due to the Biochemistry Department of the Otago Medical School for carrying out the biochemical investigation, and to colleagues for referring patients for investigation; also to Mr. G. F. Spears for statistical assistance.
Long-term dynamics of omega-5 gliadin-specific IgE levels in patients with adult-onset wheat allergy
Authors: Yuto Hamada, Yuko Chinuki, Yuma Fukutomi, Eiji Nakatani, Akiko Yagami, Kayoko Matsunaga, Yoshiko Oda, Atsushi Fukunaga, Atsuko Adachi, Makiko Hiragun, Michihiro Hide, Eishin Morita
Journal: Journal of Allergy and Clinical Immunology (2020)
In Vitro models and methods for bioassay and studies of cellular mechanisms.
Authors: Sidney Belman, Bruce Casto, C Flessel, Bernard Lane, Lawrence Loeb, Toby Rossman, Michael Sirover, Harri Vainio, Robert Whiting
Journal: Environmental Health Perspectives (1981)

Relationship Between In Vivo and In Vitro TestingThis report discusses the use of in vitro systems to detect metal carcinogens and to provide infornation on the mechanisms of metal carcinogenesis.The use of in vivo systems is also discussed, where they may provide additional information.Even though no single system has proven adequate for the definitive identification of all metal mutagens and carcinogens, the aggregate results of these studies indicate that the combined use of several systems may provide a valuable, initial screen for metals and their compounds.It is now imperative to evaluate more complex aggregates and mixtures of metals and their compounds that are environ- mentally ubiquitous (1).Metals appear to behave similarly to other carcinogens in cell transformation tests; however, they are frequently negative in bacterial mutagenesis revertant assays.In addition to rapid screening, cellular systems are particularly advantageous for analyzing the mechanism ofmetal mutagenesis and carcinogenesis.It is only in such systems that one may be able to study the mechanism and specificity of metal- induced cellular alterations which may be causative factors in neoplasia.The physiological chemistry of different metals may vary widely.For example,
Crime on Our Minds
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Interpretation of Laboratory Tests
Authors: William R. Barclay
Journal: JAMA (1979)

This is the eighth edition of a book that first appeared in 1949. However, laboratory tests have multiplied so rapidly and their interpretation has undergone such great changes that a new edition of an old and successful book is really a new book. This is not a laboratory manual of instruction on how to perform tests nor is it a simple recitation of how diseases alter biochemical measurements. It is a series of discussions on how to use certain laboratory measurements to diagnose and follow the course of disease. It is not a profound treatise but a simply straightforward description of how tests are done, what they mean, and how they can be in error or mislead. It is an easy book to read and can be used as a reference or digested in small portions in preparation for passing examinations at several levels—medical school to board examinations and recertification.
Course of Lectures on Venereal Affections Delivered at the Hopital Du Midi, Paris
Authors: P. Ricord
Journal: BMJ (1843)

Predisposition-Effects of the gouty and scrofulous diathesis in causing gonorrhoea-Treatment-Question of identity of syphilis and gonorrhoea-Points of difference observed in the tuwo diseases.GENTLEMEN,-I will define gonorrhea " an inflam- mation of certain mucous membranes, mostly the mediate or immediate result of sexual intercourse."Synonymes.-Formerlycalled " gonorrhcea," a word which may be interpreted both as " seminal dis- charge" and " discharge from the genitals ;" it still
Carcinoma of the urinary bladder
Authors: W. L. Caldwell
Journal: JAMA (1974)

CARCINOMA of the urinary bladder is primarily a disease of the elderly, with a peak incidence among those 60 to 70 years old. Each year approximately 9,000 persons in the United States die of urinary bladder cancer, the incidence being three times as frequent in men as in women. The cause of the vast majority of urinary bladder tumors has not been determined. Nevertheless, several causative agents (such as 2-naphthalamine, xenylamine, 4-nitrobiphenyl, benzidine, phenacetin, and caffeine) have been identified as carcinogens, and an increased incidence of bladder carcinoma is reported in workers in the rubber, printing, and leather industries.<sup>1</sup> Most bladder carcinomas are transitional cell tumors of varying degrees of differentiation. Squamous cell metaplasia is seen in many transitional cell carcinomas, particularly the less well-differentiated ones. However, except when schistosomiasis is the cause, true squamous cell carcinomas are rare. Adenocarcinomas also are uncommon. On initial examination, the commonest sign
PMO-180 Raised serum immunoglobulins in chronic hepatitis C: incidence and association with genotype, liver fibrosis and sustained viral response
Authors: I-U Haq, V S Hegade, K Forrester, P B Southern, S M Moreea
Journal: Gut (2012)

<h3>Introduction</h3> Serum Immunoglobulins (Igs) are commonly raised in Chronic Hepatitis C (HCV) but their clinical significance is not fully known. There is also little information on the normalisation of Igs post HCV treatment. We aimed to assess (1) the incidence of raised Igs in HCV patients, (2) the association between the most commonly raised Ig [Immunoglobulin (IgG)] and genotype [G] and liver fibrosis and (3) the association between normalisation of IgG in those achieving sustained viral response (SVR). <h3>Methods</h3> Demographics, genotype, pre-and post-treatment Igs, Ishak liver fibrosis scores (F) and SVR of all patients undergoing treatment for HCV since 2006 was collected. Data from G2, G4, G6 and unknown genotype patients were not included in the analyses. <h3>Results</h3> 295 (n) patients were treated in the study period {Genotype 1 [G1] 71, Genotype 3 [G3] 205, males 181 (mean age 45.4); females 114 (mean age 41.3)}. 217/295 (73%) patients had raised pre-treatment Igs-either alone or in combination. Raised pre-treatment IgG, IgM and IgA were seen in 32%, 22% and 11% of G1 and in 56%, 16% and 8% of G3 patients respectively. A significant association between viral genotype and raised pre-treatment level was seen only with IgG (p=0.0009) and not with IgA (p=0.46) or IgM (p=0.20). In G1, 43% of patients with advanced fibrosis (F&gt;4) had raised pre-treatment IgG compared to 29% of patients with F≤4 [non-significant (NS) association, p=0.66]. However in G3 advanced fibrosis (F&gt;4) was significantly associated with raised pre-treatment IgG [33/41 (80%) with F&gt;4 vs 70/130 (54%) with F≤4, p=0.0031] suggesting that pre-treatment IgG can be a good predictor of advanced fibrosis in G3. Overall SVR was achieved in 34% in G1 and 65% in G3. In those who achieved SVR, normalisation of raised IgG was seen more in G3 than in G1 [52% vs 44%, NS association, p=0.72]. <h3>Conclusion</h3> Our study confirms: (1) Presence of raised serum immunoglobulins, particularly that of IgG is common in both G1 and G3 patients. (2) Significant association between raised pre-treatment IgG and advanced fibrosis is seen in G3 but not in G1. In G3, pre-treatment IgG level can be good predictor of advanced fibrosis. (3) Post-SVR normalisation of IgG is seen more in G3 than in G1. <h3>Competing interests</h3> None declared.
CHRONIC, HYPERPLASTIC TUBERCULOSIS OF CECUM.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Klin Monatsbl für Augenheilkunde, Stuttgart
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New test speeds detection of E. coli.
Journal: Environmental Health Perspectives (1998)

Assessment Branch, may cause neurological damage, as well as harm to the lungs and the reproductive system."We didn't feel like those areas were adequately evaluated [in con- sidering exposure from MMT]," he says.Davis notes studies that show workers who were occupationally exposed to manganese were subject to pneumonia and coughs.He also cites a 1973 study that suggested an increase in respiratory illnesses in Japanese stu- dents lingneara fctryemitngmangnese A draft toxicological profile for manganese prepared by the ATSDR cites studies showing that men occupationally exposed to man- ganese have impaired fertility as well as impo- tence and loss oflibido.However, data on the health effects of manganese exposure are scanty and incondusive, according to the profile.Moreover, says Monica Campbell, a Toronto toxicologist and spokesperson for the Ontario Public Health Association, studies of MMT have failed to consider the impact of manganese from MMT on people living near major arterial roads.They are a vulnerable population more exposed to vehide exhausts, she says.A study of laboratory rats, presented at the Arkansas conference by researchers Hans Tjalve and Jorgen Henriksson of the Swedish University ofAgricultural Sciences in Uppsala, found that, when inhaled through the nose, manganese can enter the brain and reach the spinal column.Says EPA neuroscientist Kenneth Hudnell, "This is a whole new route of exposure that hasn't been considered before.It bypasses all protective barriers that we have."And in an EPA-funded study, Donna Mergler, a neurophysiologist at the Universite du Quebec at Montreal, and colleagues found a relationship between manganese levels in the blood and neuromotor slowing problems in people who lived near, but did not work' in, a former manganese alloy production plant.Higher blood manganese levels were also linked to learning and memory problems in men over the age of 50.But the findings from this research are preliminary, cautions Hudnell, who was a researcher on the study."It simply points out the need for more research," he says.Donald Lynam, an Ethyl vice president and scientist, takes a different view.Lynam says that MMT adds virtually no manganese to the air.He points to the condusions of an Ethyl-sponsored study, also presented at the Arkansas conference, that found that MMT's contribution of manganese to the air in Toronto was trivial.He further points to a review by the Canadian agency Health Canada that condudes that it is impossible to assess the impact of MMT on manganese in the air.The 1994 review, however, did recommend monitoring for MMT because use of the additive has
APRIL 4 IS MISSING!
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Appendicitis.
Authors: R. E. Haughton
Journal: JAMA (1898)

Richmond, Ind., Dec. 20, 1897. <h3>To the Editor:</h3> —I desire to endorse the subject matter on "Appendicitis" coming from Dr. Sterman of Evansville, Ind., in reference to "alarming mortality" following operative measures for this accident. I call it accident because it is only recently that the furore of operating in this class of cases has culminated. So that operation is advised too often, which produces the alarming mortality to which the Doctor refers. He refers to some cases, and cases of so-called "appendicitis" occur in many localities. In illustration of cases which may or may not be operated on, are those operated on too soon and those too late, with an intermediate class of cases not operated on at all, viz., those which recover; also those which die because<i>operation</i>was<i>postponed</i>till too late. I visited five cases during the past summer, two for the purpose of operation. The
Erratum
Journal: BMJ (1892)

persons or have had cases coming under their notice of those who nave abstbined from flesh as a food.The reply need merely mention the number of the question which is being answered.1. What was the effect on the physical strength and endurance?2. What was the effect on the general sense of happiness of existence?3. What was the effect on the mental clearness and perseverance ? 4. What was the effect on the passions ? 5. What constitutional ailments were affected, and in what way ?6.What was the result with regard to colds, constipation, and inflam- mation, and power of enduring heat and cold?7. What did the diet consist of, and what was the approximate daily amount ?I 8.For what length of time did the experiment last ?P. Were tea, coffee, and condiments discontinued?ANSWERS.SPAsM.-The claim will be against the executors.OUT-PATIENT REFORM AND THE INcOME TAX.A.B. (Liverpool).-Itwould serve no useful purpose to protract this discussion.The original statement that only 6,000,000 persons paid income tax is now explained to mean that only 1,290,000 separate individuals paid it according to certain calculations and estimates, in which the critical among our readers may perhaps find as much room for doubt and dispute as in the originaI statement.It is hardly likely, for instance, that they would be prepared to accept without question our correspondent's estimate of the members who pay under A, C, part of D, and E-that is to say, under three and a half of the five divisions in which payment for income tax is received-as even approximately correct, and, owing to pressure on our space.it would be impossible for us to open our columns to any further discussion of what was at best only a side issue." SOFrENING OF A WATER SUPPLY."DR. A. CODD, M.O.H. Bromley.
Epstein-Barr virus-associated lymphoproliferative eruption with progression to large granular lymphocytic leukaemia
Authors: K-H. CHO, C-W. KIM, O-S. KWON, S-G. YANG, K-C. PARK, M-H. PARK, H-I. CHO, J-G. KIM
Journal: British Journal of Dermatology (1997)
Increasing Single Epirubicin Doses in Advanced Soft Tissue Sarcomas
Authors: Massimo Lopez, Patrizia Vici, Luigi Di Lauro, Silvia Carpano
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To evaluate the maximum-tolerated dose and the clinical efficacy of epirubicin in patients with advanced soft tissue sarcoma. PATIENTS AND METHODS: Sixty-one patients were treated at three different epirubicin dose levels: 140 mg/m 2 (six patients), 160 mg/m 2 (52 patients), and 180 mg/m 2 (three patients). Cycles were repeated every 3 weeks for a maximum of eight cycles. The first two dose levels proved to be feasible and safe without dose-limiting toxicity (DLT). Because the first three patients entering the third dose level experienced DLT, subsequent patients received the next lower dose level. RESULTS: The overall response rate was 44% (95% confidence interval, ± 12%), with six complete (10%) and 21 partial (34%) responses. Responses seemed related to epirubicin dose level, because the response rate was 17%, 44%, and 100% for the three dose levels (χ 2 test for trend, P = .02). Median response duration, median time to progression, and median overall survival were 10, 8, and 15 months, respectively. Myelosuppression was the most frequent side effect, with grade 3 or 4 neutropenia occurring in 79% of the patients; 31% of patients were febrile. Nonhematologic toxicity was mainly grades 1 and 2. The mean epirubicin dose-intensity was 49 mg/m 2 per week. CONCLUSION: The third epirubicin dose level (180 mg/m 2 ) was the maximum-tolerated dose. The recommended drug dose for clinical use is 160 mg/m 2 every 3 weeks with hematopoietic support. Single high-dose epirubicin is effective as first-line treatment and should be preferentially used whenever a high response rate is important to allow the resection of an otherwise unresectable disease or whenever it might result in a significant symptomatic benefit.
Absence of true seroreversion of HIV-1 antibody in seroreactive individuals
Authors: M. J. Roy
Journal: JAMA (1993)

<h3>Objectives.</h3> —First, to determine whether there is evidence for loss of human immunodeficiency virus type 1 (HIV-1 ) antibody in seroreactive individuals. Second, if true seroreversion occurs, to determine its incidence relative to errors in the testing process. <h3>Design.</h3> —A retrospective cohort study reviewing the results of 5 446 161 HIV-1 antibody tests performed on 2 580 974 individuals (the US Army HIV Data System) from 1985 through 1992. For all patients with one or more seroreactive sample followed by one or more nonreactive sample, we examined available records and retested the samples. <h3>Participants.</h3> —Serum samples had been obtained from active-duty and retired military personnel, their dependents, and applicants to the military. <h3>Results.</h3> —Of 4911 individuals reported to be seroreactive for HIV-1 by two independent samples, only six were potential seroreverters. Review of the six cases revealed that five actually were HIV-seroreactive patients who had samples from nonreactive individuals mistakenly attributed to them, while the sixth had a testing error proven by retesting the discrepant specimen. Errors in the testing process were identified (n=23) or suspected (n=3) in another 26 individuals who had not had independent confirmation of reactivity by a second sample. The cumulative error rate was 12.4 per 1 million patients tested. An additional group of 31 uninfected infants appeared to serorevert due to loss of antibody acquired from their HIV-1— infected mothers. <h3>Conclusions.</h3> —Review of this database demonstrates no evidence for true seroreversion of HIV-1 antibody status. We conclude that if seroreversion occurs at all, it is exceedingly rare. In fact, most (if not all) cases of apparent seroreversion represent errors of attribution or testing. (<i>JAMA</i>. 1993;269:2876-2879)